Massimo Libra
Massimo Libra
Verified email at
TitleCited byYear
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance
JA McCubrey, LS Steelman, WH Chappell, SL Abrams, EWT Wong, ...
Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1773 (8), 1263-1284, 2007
Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance
JA McCubrey, LS Steelman, SL Abrams, JT Lee, F Chang, FE Bertrand, ...
Advances in enzyme regulation 46 (1), 249-279, 2006
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging
LS Steelman, WH Chappell, SL Abrams, CR Kempf, J Long, P Laidler, ...
Aging (Albany NY) 3 (3), 192, 2011
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health
WH Chappell, LS Steelman, JM Long, RC Kempf, SL Abrams, RA Franklin, ...
Oncotarget 2 (3), 135, 2011
Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia
LS Steelman, SL Abrams, J Whelan, FE Bertrand, DE Ludwig, J Bäsecke, ...
Leukemia 22 (4), 686, 2008
GSK-3 as potential target for therapeutic intervention in cancer
JA McCubrey, LS Steelman, FE Bertrand, NM Davis, M Sokolosky, ...
Oncotarget 5 (10), 2881, 2014
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance
JA McCubrey, LS Steelman, WH Chappell, SL Abrams, RA Franklin, ...
Oncotarget 3 (10), 1068, 2012
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response
JA McCubrey, LS Steelman, WH Chappell, SL Abrams, G Montalto, ...
Oncotarget 3 (9), 954, 2012
Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy
JA McCubrey, LS Steelman, SL Abrams, FE Bertrand, DE Ludwig, ...
Leukemia 22 (4), 708, 2008
Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy
LS Steelman, RA Franklin, SL Abrams, W Chappell, CR Kempf, J Bäsecke, ...
Leukemia 25 (7), 1080, 2011
Targeting the leukemic stem cell: the Holy Grail of leukemia therapy
N Misaghian, G Ligresti, LS Steelman, FE Bertrand, J Bäsecke, M Libra, ...
Leukemia 23 (1), 25, 2009
Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention
NM Davis, M Sokolosky, K Stadelman, SL Abrams, M Libra, S Candido, ...
Oncotarget 5 (13), 4603, 2014
Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway
AM Martelli, C Evangelisti, W Chappell, SL Abrams, J Bäsecke, F Stivala, ...
Leukemia 25 (7), 1064, 2011
Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention
JA McCubrey, LS Steelman, FE Bertrand, NM Davis, SL Abrams, ...
Leukemia 28 (1), 15, 2014
PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches
G Ligresti, L Militello, LS Steelman, A Cavallaro, F Basile, F Nicoletti, ...
Cell cycle 8 (9), 1352-1358, 2009
The tumor microenvironment in hepatocellular carcinoma
GC Leonardi, S Candido, M Cervello, D Nicolosi, F Raiti, S Travali, ...
International journal of oncology 40 (6), 1733-1747, 2012
Melanoma: molecular pathogenesis and emerging target therapies
AE Russo, E Torrisi, Y Bevelacqua, R Perrotta, M Libra, JA McCubrey, ...
International journal of oncology 34 (6), 1481-1489, 2009
Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways
JA McCubrey, LS Steelman, CR Kempf, WH Chappell, SL Abrams, ...
Journal of cellular physiology 226 (11), 2762-2781, 2011
Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use
GM Nitulescu, D Margina, P Juzenas, Q Peng, OT Olaru, E Saloustros, ...
International journal of oncology 48 (3), 869-885, 2016
Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors
LS Steelman, PM Navolanic, ML Sokolosky, JR Taylor, BD Lehmann, ...
Oncogene 27 (29), 4086, 2008
The system can't perform the operation now. Try again later.
Articles 1–20